The European Medicines Agency (EMA) said that its human medicines committee (CHMP) initiated the first ‘rolling review’ of a Covid-19 vaccine, developed by AstraZeneca and the University of Oxford.
CHMP started reviewing the first batch of non-clinical data on the vaccine from laboratory studies, continuing until sufficient data is available for a final decision on marketing authorisation.
Go deeper with GlobalData
A statement from EMA said: “This does not mean that a conclusion can be reached yet on the vaccine’s safety and effectiveness, as much of the evidence is still to be submitted to the committee.”
A rolling review will expedite the evaluation of promising drugs or vaccines during a public health emergency.
Commonly, all effectiveness, safety and quality data, as well as necessary documentation, must be filed with a formal application at the beginning of the review.
However, in case of a rolling review, the CHMP evaluates data as it becomes available from ongoing studies. If the committee subsequently decides that enough data is available, the company should submit a formal application.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCHMP decided to commence a real-time review of the Covid-19 vaccine based on preliminary results from non-clinical and early clinical studies. Data indicated that the vaccine elicits antibodies and T cells against the virus.
Results from ongoing large-scale trials should be available over the coming weeks and months. These findings should offer insights into the vaccine’s effectiveness in protecting people against Covid-19.
The committee will also evaluate all safety and quality data from these studies.
EMA added: “EMA will complete its assessment according to its usual standards for quality, safety and effectiveness.
“While the overall review timeline cannot be forecast yet, the process should be shorter than a regular evaluation due to the time gained during the rolling review.”
The agency used a similar rolling review process to assess Gilead Science’s Covid-19 drug, Veklury (remdesivir).
